RT Journal Article
SR Electronic
T1 PET of Somatostatin Receptor–Positive Tumors Using <sup>64</sup>Cu- and <sup>68</sup>Ga-Somatostatin Antagonists: The Chelate Makes the Difference
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1110
OP 1118
DO 10.2967/jnumed.111.087999
VO 52
IS 7
A1 Fani, Melpomeni
A1 Del Pozzo, Luigi
A1 Abiraj, Keelara
A1 Mansi, Rosalba
A1 Tamma, Maria Luisa
A1 Cescato, Renzo
A1 Waser, Beatrice
A1 Weber, Wolfgang A.
A1 Reubi, Jean Claude
A1 Maecke, Helmut R.
YR 2011
UL http://jnm.snmjournals.org/content/52/7/1110.abstract
AB Somatostatin-based radiolabeled peptides have been successfully introduced into the clinic for targeted imaging and radionuclide therapy of somatostatin receptor (sst)–positive tumors, especially of subtype 2 (sst2). The clinically used peptides are exclusively agonists. Recently, we showed that radiolabeled antagonists may be preferable to agonists because they showed better pharmacokinetics, including higher tumor uptake. Factors determining the performance of radioantagonists have only scarcely been studied. Here, we report on the development and evaluation of four 64Cu or 68Ga radioantagonists for PET of sst2-positive tumors. Methods: The novel antagonist p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2 (LM3) was coupled to 3 macrocyclic chelators, namely 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), and DOTA. 64/natCu- and 68/natGa-NODAGA-LM3 were prepared at room temperature, and 64/natCu-CB-TE2A-LM3 and 68/natGa-DOTA-LM3 were prepared at 95°C. Binding affinity and antagonistic properties were determined with receptor autoradiography and immunofluorescence microscopy using human embryonic kidney (HEK)-sst2 cells. In vitro internalization and dissociation was evaluated using the same cell line. Biodistribution and small-animal PET studies were performed with HEK-sst2 xenografts. Results: All metallopeptides demonstrated antagonistic properties. The affinities depend on chelator and radiometal and vary about 10-fold; 68/natGa-NODAGA-LM3 has the lowest half maximal inhibitory concentration (1.3 ± 0.3 nmol/L). The biodistribution studies show impressive tumor uptake at 1 h after injection, particularly of 64Cu- and 68Ga-NODAGA-LM3 (∼40 percentage injected dose per gram of tissue [%ID/g]), which were proven to be specific. Background clearance was fast and the tumor washout relatively slow for 64Cu-NODAGA-LM3 (∼15 %ID/g, 24 h after injection) and almost negligible for 64Cu-CB-TE2A-LM3 (26.9 ± 3.3 %ID/g and 21.6 ± 2.1 %ID/g, 4 and 24 h after injection, respectively). Tumor–to–normal-tissue ratios were significantly higher for 64Cu-NODAGA-LM3 than for 64Cu-CB-TE2A-LM3 (tumor-to-kidney, 12.8 ± 3.6 and 1.7 ± 0.3, respectively; tumor-to-muscle, 1,342 ± 115 and 75.2 ± 8.5, respectively, at 24 h, P &lt; 0.001). Small-animal PET shows clear tumor localization and high image contrast, especially for 64Cu- and 68Ga-NODAGA-LM3. Conclusion: This article demonstrates the strong dependence of the affinity and pharmacokinetics of the somatostatin-based radioantagonists on the chelator and radiometal. 64Cu- and 68Ga-NODAGA-LM3 and 64Cu-CB-TE2A-LM3 are promising candidates for clinical translation because of their favorable pharmacokinetics and the high image contrast on PET scans.